Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1

Interventions

Cytarabine 84Etoposide 31Daunorubicin 31Mitoxantrone 26Idarubicin 26Filgrastim 24Busulfan 20Peripheral Blood Stem Cell Transplantation 19Cyclophosphamide 17fludarabine phosphate 15Gemtuzumab 14tipifarnib 11Azacitidine 11Methotrexate 10Clofarabine 10sargramostim 9Gene Expression Profiling 9Flow Cytometry 9Cyclosporine 9Tacrolimus 8Radiotherapy 8Granulocyte Colony-Stimulating Factor 7Decitabine 7Antilymphocyte Serum 7alvocidib 6Topotecan 6Bortezomib 6Arsenic Trioxide 6valspodar 5aldesleukin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Monocytic, Acute × Bromodeoxyuridine × Clear all
NCT00003405 2021-10-14

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia

Rush University Medical Center

Phase 2 Withdrawn
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡